Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain

31 Aug 2016

Abstract excerpt

Androgen receptor (AR) is a validated drug target for all stages of prostate cancer including metastatic castration-resistant prostate cancer (CRPC). All current hormone therapies for CRPC target the C-terminal ligand-binding domain of AR and ultimately all fail with resumed AR transcriptional activity. Within the AR N-terminal domain (NTD) is activation function-1 (AF-1) that is essential for AR transcriptional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Prostate Cancer Treatment and Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27576691
DOI: 10.1074/jbc.m116.734475

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal DomainPMID 27576691Read ↗

A sting in the tail: the N-terminal domain of the androgen receptor as a drug targetSemantic proximity Read ↗

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read ↗

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate CancerSemantic proximity Read ↗

Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancerSemantic proximity Read ↗

FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variantsSemantic proximity Read ↗

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive reviewSemantic proximity Read ↗

A novel small-molecule androgen receptor antagonist selective for the T878A-mutant AR in prostate cancer therapy.Semantic proximity Read ↗

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.Semantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

Androgen Receptor (AR) Coregulators: An OverviewSemantic proximity Read ↗

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell GrowthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.